Todd Davis compensation by year
LIGAND PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $49,243 | $650,007 | $695,834 | $724,500 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $79,607 | $3,378,456 | $6,429,536 | $5,520,493 |
| Option awards | $5,001,298 | $1,788,095 | $5,142,650 | $4,441,120 |
| Non-equity incentive | $0 | $390,000 | $637,000 | $764,400 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $65,021 | $9,960 | $9,960 | $21,582 |
| Total | $5,195,169 | $6,216,518 | $12,914,980 | $11,472,095 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: LIGAND PHARMACEUTICALS INC DEF 14A filed April 21, 2026, accession 0000886163-26-000021, and prior-year filings.
How this page was built: the LIGAND PHARMACEUTICALS INC filed document, accession 0000886163-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 48,674 | $9,202,793 | — |
| PSU | 39,644 | $7,495,491 | — |
| PSU | 26,514 | $5,013,002 | — |
| PSU | 10,391 | $1,964,626 | — |
| Option | 71,350 | — | $89.20 |
| Option | 33,000 | — | $69.70 |
| Option | 520 | — | $67.03 |
| Option | 13,468 | — | $75.09 |
| Option | 75,949 | — | $115.26 |
Per the Outstanding Equity Awards at Fiscal Year-End table in LIGAND PHARMACEUTICALS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 21, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-30 | Other | — | 132 | $160.71 | 199,513 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
LIGAND PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Todd Davis · this page | Chief Executive Officer | $11,472,095 |
| Tavo Espinoza | Chief Financial Officer | $4,382,148 |
| Andrew Reardon | Chief Legal Officer and Secretary | $3,747,282 |
Board service
LIGAND PHARMACEUTICALS board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | $0 | $0 | $0 | — |
| FY2024 | — | — | — | — | — |
| FY2022 | — | — | — | — | — |
| FY2021 | $65,051 | $72,696 | $190,060 | — | $327,807 |
Each year as the company reported it in LIGAND PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: LIGAND PHARMACEUTICALS pays directors a $42,000 cash retainer and $375,000 in RSUs and Options. As stated in LIGAND PHARMACEUTICALS's FY2025 proxy.
The full LIGAND PHARMACEUTICALS compensation record
free company briefThis page is one person within LIGAND PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the LIGAND PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order LIGAND PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are LIGAND PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.